Beam Therapeutics (NASDAQ:BEAM) Stock Moved Down to “Strong Sell” by Wall Street Zen

Wall Street Zen downgraded shares of Beam Therapeutics (NASDAQ:BEAM) from a sell rating to a strong sell rating in a research note released on Saturday morning,Wall Street Zen reports.

Other analysts have also recently issued reports about the company. Bank of America reissued a “buy” rating and set a $47.00 price target on shares of Beam Therapeutics in a report on Wednesday, July 8th. Canaccord Genuity Group upped their price objective on Beam Therapeutics from $78.00 to $79.00 and gave the company a “buy” rating in a report on Thursday. Wedbush lowered their price objective on Beam Therapeutics from $65.00 to $28.00 and set an “outperform” rating on the stock in a research report on Wednesday. HC Wainwright reiterated a “buy” rating on shares of Beam Therapeutics in a research report on Tuesday. Finally, William Blair raised Beam Therapeutics to a “strong-buy” rating in a report on Wednesday, September 23rd. One equities research analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, Beam Therapeutics currently has a consensus rating of “Moderate Buy” and a consensus price target of $46.90.

Beam Therapeutics Trading Down 5.6%

Shares of BEAM stock opened at $27.23 on Friday. Beam Therapeutics has a 12-month low of $20.23 and a 12-month high of $38.26. The company has a market capitalization of $2.81 billion, a PE ratio of -31.66 and a beta of 2.20. The firm has a 50 day moving average price of $25.93 and a two-hundred day moving average price of $28.19. The company has a quick ratio of 14.57, a current ratio of 14.57 and a debt-to-equity ratio of 0.09.

Beam Therapeutics (NASDAQ:BEAM) last posted its earnings results on Tuesday, August 4th. The company reported ($1.18) EPS for the quarter, missing the consensus estimate of ($1.11) by ($0.07). Beam Therapeutics had a negative net margin of 54.75% and a negative return on equity of 30.71%. The firm had revenue of $0.49 million during the quarter, compared to analyst estimates of $16.37 million. During the same period in the previous year, the company posted ($1.00) EPS. Beam Therapeutics’s revenue for the quarter was down 94.2% compared to the same quarter last year. As a group, analysts predict that Beam Therapeutics will post -4.49 earnings per share for the current year.

Insider Activity at Beam Therapeutics

In other news, CEO John Evans sold 25,000 shares of the firm’s stock in a transaction that occurred on Thursday, October 15th. The shares were sold at an average price of $23.57, for a total transaction of $589,250.00. Following the transaction, the chief executive officer directly owned 1,047,205 shares of the company’s stock, valued at approximately $24,682,621.85. This trade represents a 2.33% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Corporate insiders own 3.80% of the company’s stock.

Institutional Investors Weigh In On Beam Therapeutics

Several institutional investors have recently made changes to their positions in BEAM. Mirae Asset Global Investments Co. Ltd. acquired a new position in Beam Therapeutics in the third quarter valued at about $129,000. Profund Advisors LLC lifted its position in Beam Therapeutics by 10.0% during the third quarter. Profund Advisors LLC now owns 52,359 shares of the company’s stock worth $1,280,000 after purchasing an additional 4,775 shares during the period. China Universal Asset Management Co. Ltd. lifted its position in Beam Therapeutics by 15.1% during the third quarter. China Universal Asset Management Co. Ltd. now owns 18,846 shares of the company’s stock worth $462,000 after purchasing an additional 2,473 shares during the period. D.A. Davidson & CO. grew its stake in Beam Therapeutics by 5.0% during the third quarter. D.A. Davidson & CO. now owns 105,697 shares of the company’s stock worth $2,584,000 after buying an additional 5,069 shares in the last quarter. Finally, Sterling Capital Management LLC grew its stake in Beam Therapeutics by 504.0% during the third quarter. Sterling Capital Management LLC now owns 3,135 shares of the company’s stock worth $77,000 after buying an additional 2,616 shares in the last quarter. 99.68% of the stock is currently owned by institutional investors.

Beam Therapeutics News Roundup

Here are the key news stories impacting Beam Therapeutics this week:

• Positive Sentiment: Clinical optimism remains a potential support. Beam reviewed initial Phase 1/2 data for BEAM-301 in glycogen storage disease type 1a, keeping investor attention on the company’s base-editing pipeline and future milestone potential. Beam Therapeutics reviews initial BEAM-301 data
• Positive Sentiment: Citi initiated or reiterated a Buy view on Beam, while broader healthcare commentary also identified BEAM among attractive stocks. This reinforces the bullish long-term case centered on gene editing and potential pipeline catalysts. Beam Therapeutics gets a Buy from Citi
• Positive Sentiment: Shares previously gained 15.6% on above-average volume, suggesting strong short-term interest. However, the accompanying analysis cautioned that recent earnings-estimate trends may not sustain the rally. Beam Therapeutics moves 15.6% higher
• Neutral Sentiment: Beam crossed above its 200-day moving average, a potentially constructive technical signal, but the report tied the move to an analyst downgrade, limiting its significance. Beam crosses above its 200-day moving average
• Negative Sentiment: Wedbush cut its price target, adding pressure to the stock after its recent advance. The downgrade signals more cautious near-term expectations even as other analysts remain constructive. Wedbush cuts Beam Therapeutics price target
• Negative Sentiment: HC Wainwright retained a Buy rating but lowered most 2026–2029 EPS forecasts, including FY2026 to a loss of $4.67 per share and FY2027 to a loss of $5.23. The revisions highlight continued heavy losses and delayed profitability; FY2030 was modestly improved to a $1.48 loss. HC Wainwright earnings estimate revisions

About Beam Therapeutics

Beam Therapeutics Inc is a biotechnology company developing precision genetic medicines for patients with serious diseases. The company’s platform uses base editing, a form of gene editing designed to make targeted changes to individual DNA letters without creating double-strand breaks. Beam is also advancing related editing technologies and delivery systems intended to improve the precision and effectiveness of genetic treatments.

Beam’s pipeline includes investigational programs for diseases such as sickle cell disease, beta thalassemia, alpha-1 antitrypsin deficiency and glycogen storage disease type Ia.